累計超7億劑次
5天增1億劑次！
在新冠疫苗接種上
“中國速度”足以令世界矚目
6月3日，美聯社在其一篇文章中指出：中國正在做一件世界上其他國傢根本不能做到的事情：以驚人的速度（at a staggering pace）推進疫苗接種。
美聯社一篇題為《起步雖晚，但中國正以驚人速度推進疫苗接種計劃》的文章
文章首先關註到中國疫苗接種的數據，稱中國在上個月的短短5天內，就接種瞭1億劑次新冠肺炎疫苗。
In the span of just five days last month, China gave out 100 million shots of its COVID-19 vaccines.
文章認為，中國正在做一件世界其它國傢根本做不到的事情：運用廣泛的影響力和成熟的國內疫苗產業，以驚人的速度推進接種。
After a slow start, China is now doing what virtually no other country in the world can: leveraging the power and a maturing domestic vaccine industry to administer shots at a staggering pace.
來源：新華社
以下為文章核心觀點：
截至周三（6月2日），中國已接種瞭超過7.04億劑次疫苗，其中近一半是5月份發放的。根據牛津大學在線研究網站“以數據看世界”的數據，全球目前共接種瞭約19億劑次疫苗，其中大約三分之一來自中國。
As of Wednesday, China had given out more than 704 million doses — with nearly half of those in May alone. China’s total is roughly a third of the 1.9 billion shots distributed globally, according to Our World in Data, an online research site.
根據該網站的7天滾動平均數據，中國現在平均每天大約接種1900萬劑次，相當於大約每三天就為每個意大利人接種一劑。而人口數約為中國四分之一的美國，在4月份全速推廣疫苗時，每天也僅能接種340萬劑次。
China is now averaging about 19 million shots per day, according to Our World in Data’s rolling seven-day average. That would mean a dose for everyone in Italy about every three days. The United States, with about one-quarter of China’s population, reached around 3.4 million shots per day in April when its drive was at full tilt.
在首都北京，87%的人口已至少接種瞭第一針疫苗。接種疫苗非常容易，全城有數百個疫苗接種點，“移動接種車”停在人流量大的地區，包括市中心和購物中心。
In Beijing, the capital, 87 percent of the population has received at least one dose. Getting a shot is as easy as walking into one of hundreds of vaccination points found all across the city. Vaccination buses are parked in high foot-traffic areas, including in the city center and at malls.
中國還註重為海外中國公民接種疫苗，在全球范圍內，中國已通過其“春苗行動”惠及瞭50多萬海外公民。
China has even focused on vaccinating its citizens abroad. Globally, it has vaccinated more than 500,000 overseas citizens under what it calls the “Spring Sprout” program.
5月29日，一名中國公民在孟加拉國首都達卡接種中國新冠疫苗。來源：新華社
分析師和業內人士表示，中國的疫苗制造商不太可能在生產規模上遇到問題。
It is unlikely that Chinese manufacturers will have problems with scale, according to analysts and those who have worked in the industry.
科興制藥和國藥控股生產瞭在中國分發的大部分疫苗，兩種疫苗已獲得世界衛生組織的緊急使用授權。兩傢公司都積極提高產量，建設新工廠，並對現有工廠進行改造，以應對新冠肺炎。科興方面表示年產能可達20億劑，而國藥方面表示年產能將達30億劑。
Sinovac and Sinopharm, which make the majority of the vaccines being distributed in China, have both aggressively ramped up production, building brand new factories and repurposing existing ones for COVID-19. Sinovac’s vaccine and one of the two Sinpharm makes have received an emergency authorization for use from the World Health Organization. Sinovac has said it has doubled its production capacity to 2 billion doses a year, while Sinopharm has said it can make up to 3 billion doses a year.
此外，中國疫苗公司在生產過程中基本上不依賴進口產品。當許多國傢都在爭奪相同原料之際，這是一個巨大的優勢，這意味著中國可以避免印度血清研究所一樣的遭遇。由於某些原料依賴從美國進口，該研究所的生產一度陷入困境。
Chinese vaccine companies also largely do not rely on imported products in the manufacturing process. That’s an enormous benefit at a time when many countries are scrambling for the same materials and means China can likely avoid what happened to the Serum Institute of India, whose production was hobbled because of dependence on imports from the US for certain ingredients.